Antibody therapeutics companies develop engineered antibodies that target specific molecules involved in disease. These medicines are used across oncology, autoimmune disease, inflammatory conditions, infectious disease and other areas of clinical development.
This category includes companies working on:
Browse 68 UK antibody therapeutics companies below.
Global pharma company in immunology, vaccines, and oncology
GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio…
Silica encapsulation platform eliminating cold chain for biologics
EnsiliTech is a biotechnology company developing ensilication, a patented platform technology that encases vaccines, antibodies, and other biologics within a silica matrix to…
Fibroblast immunology platform targeting cancer and inflammatory disease
Mestag Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies targeting activated fibroblasts to modulate immune responses in cancer…
Target discovery platform and antibody-based therapies for oncology
Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform…
Antibody discovery platform identifying therapeutics from resilient individuals
Alchemab Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for neurodegenerative diseases, oncology, and immunology. Its platform…
Clinical-stage antibody-drug conjugate developer for cancer
Iksuda Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat solid and haematological cancers. Its ADC platform…
Antibody fragment drug conjugate platform for solid tumour oncology
Antikor Biopharma is a pre-clinical stage biotechnology company developing antibody fragment drug conjugates for the treatment of solid tumours. The company's proprietary platform…
Engineered bacteria to remodel the tumour microenvironment
Neobe Therapeutics is a UK synthetic biology company developing programmable live biotherapeutics that colonise solid tumours and disrupt the local microenvironment to enable…
AI platform for in silico antibody discovery
Antiverse is a Cardiff-based company using machine learning to identify diverse and rare antibody candidates from next-generation sequencing data of naïve and immune repertoires.…
Monoclonal antibodies for viral infectious disease
RQ Biotechnology is a passive immunisation company discovering and developing long-acting monoclonal antibodies to provide immediate protection against viral infections in…
Virus-like particle vaccine platform for infectious disease and diagnostics
iQur is a London-based biotechnology company developing vaccines using its proprietary tandem core virus-like particle platform. The technology uses the hepatitis B virus core…
KnotBody therapeutics for ion channel and GPCR diseases
Maxion Therapeutics is a biotechnology company developing a pipeline of KnotBody therapeutics for diseases driven by ion channel and G protein-coupled receptor dysfunction. The…